Madrid, Spain and Heidelberg, Germany, 9 July 2015 - At the Annual General Meeting (AGM) of SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on 8 July 2015 shareholders representing 59 percent of the capital approved all proposals of the Management with a large majority. The main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past fiscal year, the creation of new authorized capital, as well as changes due to the authorization the Management Board to issue convertible bonds, excluding subscription rights. At the Annual General Meeting, Pilar de la Huerta, CEO and CFO of SYGNIS, highlighted financial and strategic achievements during fiscal year 2014, including the successful implementation of the new product and commercialization strategy, the launch of the first own product line based on SYGNIS’ proprietary TruePrime TM technology for primer-free whole genome amplification and the very successful expansion of the Company’s sales and marketing network by signing the first distribution agreements. For the current year, SYGNIS expects the development of further products in the field of DNA amplification and sequencing and the strengthening of its position, especially in the market for Next Generation Sequencing (NGS).
You will find further information about our AGM and the detailed voting results on our website: http://www.sygnis.com in the Investor Relations section.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi (R) , licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
Help employers find you! Check out all the jobs and post your resume.
